Buying Generic Epclusa (Sofosbuvir 400 mg + Velpatasvir 100 mg) for only US$950
How to buy generic Epclusa online from India.
The Short Story on Generic Epclusa
Gilead licensed generic Epclusa became available from India in May 2017.
The cost for 12 weeks treatment is US$950 including shipping, delivered to your door.
To order generic Epclusa, such as VelaSof or MyHep All, from India please email me for details.
I can organise shipment of generic Epclusa to most countries including the USA, Europe, Brazil and just about every other country on Earth.
Epclusa offers a number of advantages to people with Hep C. Firstly Epclusa treats all genotypes of Hep C, this means that if you do not know which genotype of Hep C you have using Epclusa will save you the cost of getting a genotype test. Epclusa is also generally considered to be the most effective treatment for Genotype 3 though it only offers a cure rate that is 1% higher than Sofosbuvir + Daclatasvir.
To buy 12 weeks treatment of Gilead Licensed generic Epclusa for US$950 (including shipping costs) Please email me for details.
Remember that when you buy your Hep C medication through Greg Jefferys Buyers’ Club:
Delivery is 100% Guaranteed
Your medication is 100% insured against any loss or damage.
Your medication is made under license from GILEAD SCIENCES in FDA and WHO approved facilities.
There is a 100% Money Back Guarantee if you are not cured Hepatitis C.
(Guarantee is provided if you take the recommended treatment for your Hepatitis C based on accepted international standards)
The Long Story
Epclusa is made by GILEAD, the same company that manufactures Sovaldi (Sofosbuvir 400 mg) and Harvoni (Sofosbuvir 400 mg + Ledipasvir 90 mg).
Whilst Harvoni was, and still is, the optimum treatment for Hep C genotype 1 it is not the best treatment for all other genotypes of Hepatitis C, which, up until the release of Epclusa, were best treated by the combination of Sofosbuvir 400 mg + Daclatasvir 60 mg.
Because Hep C genotype 1 represents about 55% of all Hep C infections GILEAD had a large part of the market covered with Harvoni however it was missing out on profits from the other half of the market, which was G3 about 25% and G2 about 15%. So because GILEAD is all about profits it was worried it was not making any money out of G2 and G3.
So GILEAD put in a lot of work to find a drug combination based around Sofosbuvir that would work against all genotypes of Hep C.
That mission was completed with the arrival of Epclusa which is made of Sofosbuvir 400 mg + Velpatasvir 100 mg.
Whilst Epclusa is not any better for treating G1 than Harvoni it is equal to, or a little better than, Sofosbuvir + Daclatasvir for treating other genotypes of Hep C.
Recent research suggests that Sofosbuvir + Velpatasvir is only about 1% better than Sofosbuvir + Daclatasvir for treating Hep C genotype 3.
However, the big advantage of Epclusa is that a person does not need to know their genotype of Hep C to begin treating the virus because Epclusa will treat all genotypes of Hepatitis C thus removing the need to take the Hep C genotype test.
For a lot of people, this is a big saving in money terms because the test for genotype generally costs over US$260.
Of course like all GILEAD products, with a price tag of around US$90,000 for 12 week’s treatment Epclusa, is grossly overpriced and out of the reach of most people who need treatment for chronic Hepatitis C.
Like all GILEAD products, the aim is to sell Epclusa at a price that maximizes profits and minimizes access, so Epclusa is only affordable to people with top level health insurance or living in wealthy countries that can afford to include it in their National Health Services.
For the other 100 million+ people with Hep C the generic Epclusa from India is a good option.
A Brief History of Generic Epclusa
The first generic Epclusa was made in Bangladesh using APIs of Sofosbuvir and Velpatasvir imported from China.
These two generic versions of Epclusa were made by Beacon Industries (SOFOSVEL) and Incepta (PANOVIR)
However whilst these products appear to be quite effective there is an issue with the drug Velpatasvir. Like the Ledipasvir used in Harvoni Velpatasvir is very difficult for the body to absorb.
That is to say Velpatasvir is essentially insoluble.
This is the opposite of Sofosbuvir, which is very soluble.
To improve the absorption of Velpatasvir GILEAD developed a technology that mixes the very small particles of Velpatasvir with some other chemicals that make it easier for the body to absorb and utilise Velpatasvir.
Generic Epclusa from India
When Epclusa was released in the USA and Europe once again India entered into negotiations with GILEAD. This time to produce a licensed generic version of Epclusa. Because part of the license agreement is that the Indian manufacturers will have access to all of GILEAD’s intellectual property, including the technology for improving absorption of Velpatasvir, this means that the Indian generic Epclusa is identical to the GILEAD branded Epclusa.
As with Harvoni two Indian pharmaceutical companies are making the generic Epclusa, these are Natco and Hetero Pharmaceuticals.
Whilst both of these companies finalised licensing agreements with GILEAD to manufacture generic Epclusa late in 2016 the India government has been a little tardy in granting these companies permission to sell generic Epclusa in India.
This permission finally came through in April 2017 and the release date for the generic Epclusa to be available for sale in India was May 2017.
The price is somewhere around US$950 to US$1,600 for a 12 week treatment, depending on who you purchase from.
How Effective is Epclusa?
One of GILEAD’s strongest attributes is its skill in sales and marketing.
Indeed, like all of Big Pharma, GILEAD spends more on marketing than it does on research.
As a result of GILEAD’s promotion of Epclusa it is widely considered the new wonder drug for Hepatitis C however in reality Epclusa is no more effective than Harvoni against Hepatitis C genotype 1 and no more effective against the other genotypes of Hepatitis C than Sofosbuvir + Daclatasvir. The one exception to this appears to be Hepatitis C genotype 3. The present research suggests that Sofosbuvir + Velpatasvir (Epclusa) may be quite a lot better for treating G3 than Sof + Daclatasvir but there is not enough research data to be certain of this at the moment.
So if you have genotype 1 there is no real advantage in using Epclusa over Harvoni.
If you have G2 than Sof+ Dac will be just as effective as Sof+Velpatasvir.
For treatment of Genotype 3 Sofosbuvir + Velpatasvir is only marginally better than Sofosbuvir + Daclatasvir but is more expensive. For Genotype 3, which ever treatment is used it is wise to be considering doing more than the recommended 12 weeks to give optimum cure rates. If it were me I would do at least 16 weeks. Recent research shows that adding Ribavirin, which is often recommended, does not improve cure rates. Because Ribavirin is quite toxic it is wise to avoid using it.
If you do not know what genotype of Hepatitis C you have and if you would have problems finding the US$200 or more for the genotype test then Epclusa is a very good idea.
Another good reason for using Epclusa is that about 10% of people with Hepatitis C are infected with more than one genotype. By using Epclusa all genotypes will be treated. Though, again, treating with Sofosbuvir + Daclatasvir would give the same results.
Order Licensed Generic Epclusa Now
I hope this is helpful to people. If you would like to order generic Epclusa online or need information about Epclusa please email me and I will help you. The cost will not be above US$950 for a 12 weeks treatment.